Previous 10 | Next 10 |
Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the retirement of Dinah Sah, Ph.D. as Voyager’s chief s...
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am...
Voyager Therapeutics (NASDAQ: VYGR ): Q1 GAAP EPS of -$0.81 misses by $0.03 . More news on: Voyager Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
FDA grants orphan-drug designation for VY-HTT01 for Huntington’s disease Begins strategic collaboration with Neurocrine Biosciences on gene therapy programs for Parkinson's disease and Friedreich's ataxia Announces Board of Directors leadership change CAMBRIDGE, Mass., ...
The following slide deck was published by Voyager Therapeutics, Inc. in conjunction with this Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ) and Voyager Therapeutics (NASDAQ: VYGR ) reports Phase I trial results for VY-AADC from eight patients with Parkinson’s disease. These Phase I results were presented at the 2019 American Academy of Neurology (AAN) Annual Meeting. More news on...
Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson’s Disease T reatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours a...
Although Neurocrine Biosciences ( NBIX ) has a strong primary commercial asset in Ingrezza, a slower-building but still promising secondary asset partnered to AbbVie ( ABBV ) in Orlissa, and an improved pipeline, the reality is that the shares of biotechs in Neurocrine’s stage of li...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...